The next frontier for India Pharma Inc is transforming into a value-driven, innovation-focused industry. This requires the industry to leverage its experience and expertise gained as a leading generics manufacturer towards the development of new molecules and biosimilars.

Fortuitously, many global companies across sectors, including pharma are looking at India to set up cutting-edge R&D centres to strengthen their capabilities and capture new markets, driven by factors such as market opportunity, technical expertise, cost efficiency, proactive government policies, as well as talented and dynamic workforce.

Therefore, FDD Conclave 2023 will bring the FR&D community together to discuss how India Pharma Inc needs to leverage its existing strengths and build new capabilities to develop of innovative and differentiated pharma products, complex drugs or biologics and biosimilars across a range of indications for its next phase of growth.

FR&D leaders will also highlight evidence-based strategies and approaches to develop novel formulations and drug delivery systems which will help create intellectual property, enhance life-cycle management, and amplify cost and market differentiation.

The leaders will also examine the impact of recent government initiatives, regulations and policies to help promote innovation in pharma R&D and help India secure and sustain a key position in the global pharma R&D landscape.